Published in Proc Natl Acad Sci U S A on September 19, 2007
Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer (2009) 4.66
Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks. Cell (2008) 3.25
Atypical E2Fs: new players in the E2F transcription factor family. Trends Cell Biol (2009) 1.56
Mouse development with a single E2F activator. Nature (2008) 1.51
C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. Blood (2010) 1.28
c-Myc induction of programmed cell death may contribute to carcinogenesis: a perspective inspired by several concepts of chemical carcinogenesis. Cancer Biol Ther (2011) 1.04
Emi1 maintains genomic integrity during zebrafish embryogenesis and cooperates with p53 in tumor suppression. Mol Cell Biol (2009) 0.97
EKLF directly activates the p21WAF1/CIP1 gene by proximal promoter and novel intronic regulatory regions during erythroid differentiation. Mol Cell Biol (2010) 0.97
E2f2 induces cone photoreceptor apoptosis independent of E2f1 and E2f3. Cell Death Differ (2013) 0.92
A role for E2F activities in determining the fate of Myc-induced lymphomagenesis. PLoS Genet (2009) 0.90
E2F2 suppresses Myc-induced proliferation and tumorigenesis. Mol Carcinog (2010) 0.87
Methylation-independent repression of Dnmt3b contributes to oncogenic activity of Dnmt3a in mouse MYC-induced T-cell lymphomagenesis. Oncogene (2015) 0.87
Selective roles of E2Fs for ErbB2- and Myc-mediated mammary tumorigenesis. Oncogene (2013) 0.86
miR-155 regulates the proliferation and invasion of clear cell renal cell carcinoma cells by targeting E2F2. Oncotarget (2016) 0.82
E2F1 and E2F2 prevent replicative stress and subsequent p53-dependent organ involution. Cell Death Differ (2015) 0.81
Targeting the RB-E2F pathway in breast cancer. Oncogene (2016) 0.81
RNAi-mediated knockdown of E2F2 inhibits tumorigenicity of human glioblastoma cells. Oncol Lett (2014) 0.80
Inhibition of p300 lysine acetyltransferase activity by luteolin reduces tumor growth in head and neck squamous cell carcinoma (HNSCC) xenograft mouse model. Oncotarget (2015) 0.78
Upregulation of E2F8 promotes cell proliferation and tumorigenicity in breast cancer by modulating G1/S phase transition. Oncotarget (2016) 0.78
Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer. Oncotarget (2016) 0.78
Molecular and cellular pathways associated with chromosome 1p deletions during colon carcinogenesis. Clin Exp Gastroenterol (2011) 0.77
MiR-218 Inhibited Growth and Metabolism of Human Glioblastoma Cells by Directly Targeting E2F2. Cell Mol Neurobiol (2015) 0.76
E2F2 induction in related to cell proliferation and poor prognosis in non-small cell lung carcinoma. Int J Clin Exp Pathol (2015) 0.76
Reduced expression of the retinoblastoma protein shows that the related signaling pathway is essential for mediating the antineoplastic activity of erufosine. PLoS One (2014) 0.75
Epigallocatechin-3-gallate Modulates MicroRNA Expression Profiles in Human Nasopharyngeal Carcinoma CNE2 Cells. Chin Med J (Engl) (2017) 0.75
Dosage-dependent copy number gains in E2f1 and E2f3 drive hepatocellular carcinoma. J Clin Invest (2017) 0.75
CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev (1999) 24.83
Proliferation, cell cycle and apoptosis in cancer. Nature (2001) 9.57
Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell (1999) 8.03
The RB and p53 pathways in cancer. Cancer Cell (2002) 8.02
Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol (2002) 7.64
Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol (2005) 7.54
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev (1999) 6.87
c-MYC: more than just a matter of life and death. Nat Rev Cancer (2002) 6.73
E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell (1996) 5.26
The E2F transcriptional network: old acquaintances with new faces. Oncogene (2005) 4.87
Tumor induction and tissue atrophy in mice lacking E2F-1. Cell (1996) 4.80
Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res (2005) 4.60
E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev (1998) 4.60
The E2F1-3 transcription factors are essential for cellular proliferation. Nature (2001) 4.37
Pocket proteins and cell cycle control. Oncogene (2005) 4.11
The E2F family: specific functions and overlapping interests. EMBO J (2004) 3.33
Inactivating E2f1 reverts apoptosis resistance and cancer sensitivity in Trp53-deficient mice. Nat Cell Biol (2003) 3.05
E2F4 and E2F5 play an essential role in pocket protein-mediated G1 control. Mol Cell (2000) 2.48
Myc requires distinct E2F activities to induce S phase and apoptosis. Mol Cell (2001) 2.29
A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. Nature (2000) 2.10
Mutation of E2F2 in mice causes enhanced T lymphocyte proliferation, leading to the development of autoimmunity. Immunity (2001) 2.09
E2F1 and E2F2 determine thresholds for antigen-induced T-cell proliferation and suppress tumorigenesis. Mol Cell Biol (2001) 1.91
Signaling networks that link cell proliferation and cell fate. J Biol Chem (2002) 1.91
Loss of CBP causes T cell lymphomagenesis in synergy with p27Kip1 insufficiency. Cancer Cell (2004) 1.80
Defective gene expression, S phase progression, and maturation during hematopoiesis in E2F1/E2F2 mutant mice. Mol Cell Biol (2003) 1.56
Oncogene addiction: sometimes a temporary slavery. Cancer Cell (2004) 1.54
Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss. Mol Cell (2003) 1.47
Combinatorial gene control involving E2F and E Box family members. EMBO J (2004) 1.35
Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis. EMBO J (2007) 1.29
Conditionally MYC: insights from novel transgenic models. Cancer Lett (2004) 1.10
Transgenic analysis of thymocyte signal transduction. Nat Rev Immunol (2002) 1.05
Lymphomagenesis and female-specific lethality in p53-deficient mice occur independently of E2f1. Nat Cell Biol (2004) 0.85
Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science (2002) 17.38
Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol (2010) 5.62
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature (2004) 5.61
MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A (2012) 5.07
MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med (2008) 4.91
HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell (2007) 4.81
Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer (2009) 4.66
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med (2013) 4.49
Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature (2009) 4.21
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood (2013) 4.17
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol (2008) 4.09
miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell (2010) 4.07
Extra-embryonic function of Rb is essential for embryonic development and viability. Nature (2003) 3.92
Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood (2007) 3.73
MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer (2010) 3.64
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell (2005) 3.44
Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res (2008) 3.41
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A (2007) 3.37
CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell (2010) 3.33
Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. J Immunol (2002) 3.30
Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med (2006) 3.29
Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. J Clin Invest (2006) 3.27
Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest (2012) 3.14
Human natural killer cell development. Immunol Rev (2006) 3.14
A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity (2005) 3.14
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol (2005) 3.05
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol (2011) 3.01
Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med (2005) 3.01
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol (2008) 2.98
The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant (2006) 2.93
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest (2007) 2.91
Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol (2013) 2.86
In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood (2002) 2.85
Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology (2005) 2.80
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol (2009) 2.78
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood (2009) 2.75
BNDB - the Biochemical Network Database. BMC Bioinformatics (2007) 2.75
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A (2006) 2.72
NK cell and DC interactions. Trends Immunol (2004) 2.68
Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue. Immunity (2010) 2.67
Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet (2005) 2.63
Synergistic function of E2F7 and E2F8 is essential for cell survival and embryonic development. Dev Cell (2008) 2.61
Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity (2006) 2.56
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood (2011) 2.50
Retinoblastoma promotes definitive erythropoiesis by repressing Id2 in fetal liver macrophages. Nature (2004) 2.49
BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet (2001) 2.46
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw (2010) 2.45
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood (2010) 2.41
Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol (2005) 2.41
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood (2009) 2.39
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell (2010) 2.37
Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. Nat Med (2009) 2.31
What does it take to make a natural killer? Nat Rev Immunol (2003) 2.30
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood (2003) 2.23
E2f1-3 switch from activators in progenitor cells to repressors in differentiating cells. Nature (2009) 2.22
Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood (2002) 2.20
Genomic alterations in tumor stroma. Cancer Res (2009) 2.18
Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH 17 cytokine interleukin-22. Blood (2009) 2.18
Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis. Blood (2009) 2.17
Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood (2013) 2.16
An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. Nat Med (2008) 2.12
BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell (2003) 2.08
DIALIGN-TX: greedy and progressive approaches for segment-based multiple sequence alignment. Algorithms Mol Biol (2008) 2.07
Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. Leuk Lymphoma (2009) 2.06
Developmental context determines latency of MYC-induced tumorigenesis. PLoS Biol (2004) 2.05
Identification and characterization of E2F7, a novel mammalian E2F family member capable of blocking cellular proliferation. J Biol Chem (2003) 2.04
Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell (2012) 2.01
Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol (2012) 1.98
Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood (2012) 1.97
Cloning and characterization of mouse E2F8, a novel mammalian E2F family member capable of blocking cellular proliferation. J Biol Chem (2005) 1.95